Last list of reimbursed drugs 2025. Record

- This announcement has the highest ever number of additional therapies added for reimbursement. The year 2025 is also historic for the fact that 151 new therapies included in the four announcements have been added to the lists," said Deputy Drug Minister Katarzyna Kacperczyk, who made her debut in the role responsible for drug policy with Monday's conference on the presentation of the new reimbursement list.

Among the new 50 molecules are 22 oncology therapies, 28 non-oncology therapies. Twelve therapies are for rare and ultra-rare diseases. Three new drug technologies will be funded under the Medical Fund. Four oncology therapies are included in the list of drugs with well-established efficacy, which makes the therapy more widely available and more accessible to patients. We also have changes to the lists to expand indications for many therapies compared to existing indications," Kacperczyk enumerated.

Matthew Oczkowski, deputy director of the Department of Drug Policy and Pharmacy, assessed that the most important developments of this announcement are three areas. - The first is the oncology indication, which means continuing to work on increasing the availability of products with oncology indications, this time in the gynecological and breast cancer aspects, he said. The second area is the treatment of hypercholesterolemia. - Availability of drugs that have remarkable efficacy even in actual clinical practice has been limited until now. Ultimately, we will achieve a population effect, which was highly anticipated in the cardiology community, as well as patients," he stressed.

- The third element is the most emotionally charged, which is the issue of hemophilia treatment. We didn't want one commercial product to really obscure all of our achievements in terms of making things available to patients. You can see that lobbying circles are getting stronger and stronger, and they actually want to exert pressure by operating in the public space, which is not allowed by the Ministry of Health. Hemophilia patients have the widest access of all disease entities and the best organization of the system," Oczkowski stressed.

Katherine Kacperczyk said the ministry is working on improving the B.15 drug program (hemophilia treatment). - We're going to unify it, and I think we're moving in the right direction, we're taking advantage of international experience, we're listening to different communities. We would very much prefer not to have concerns or confusion about one commercial product cast a shadow over the overall approach to hemophilia treatment," she noted.

Both Deputy Minister Katarzyna Kacperczyk and Mateusz Oczkowski made no secret of their hope for close cooperation with the departments responsible for benefits and the treatment area, which report to Deputy Minister Tomasz Maciejewski. The idea is that expanding the list of reimbursed drugs should go hand in hand with improving access to diagnostics - at the moment, patients have only theoretical access to some innovative therapies, because they have to wait too long for the tests themselves or their results.